Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma
Authors
Keywords
-
Journal
Frontiers in Molecular Biosciences
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-12-21
DOI
10.3389/fmolb.2020.566291
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
- (2020) William D. Tap et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Targets for Bone and Soft-Tissue Sarcomas
- (2019) Shinji Miwa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Applicability of drug response metrics for cancer studies using biomaterials
- (2019) Elizabeth A. Brooks et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
- (2019) Ruben D. Addie et al. Journal of Bone Oncology
- Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
- (2019) Sanne Venneker et al. Cancers
- Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance
- (2018) Karen Boehme et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine
- (2018) Gianluca Colella et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Spheroid-based 3D cell cultures identify salinomycin as a promising drug for the treatment of chondrosarcoma
- (2018) Francesca Perut et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- A Phase I Trial of the IGF‐1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer
- (2018) Gordana Vlahovic et al. ONCOLOGIST
- Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas
- (2018) V.M. van Praag (Veroniek) et al. SURGICAL ONCOLOGY-OXFORD
- Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
- (2018) Janeta Popovici-Muller et al. ACS Medicinal Chemistry Letters
- Survival and prognostic factors in conventional central chondrosarcoma
- (2018) Julian Fromm et al. BMC CANCER
- Outcome of First‐Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma
- (2018) Annemiek van Maldegem et al. ONCOLOGIST
- Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
- (2018) Yvonne de Jong et al. Oncogenesis
- QuPath: Open source software for digital pathology image analysis
- (2017) Peter Bankhead et al. Scientific Reports
- No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone
- (2016) Elisabeth F. P. Peterse et al. BMC CANCER
- Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
- (2016) D. Katz et al. BMC CANCER
- Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line
- (2016) Yvonne de Jong et al. LABORATORY INVESTIGATION
- Screening out irrelevant cell-based models of disease
- (2016) Peter Horvath et al. NATURE REVIEWS DRUG DISCOVERY
- Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy
- (2016) Damien C. Weber et al. RADIOTHERAPY AND ONCOLOGY
- Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
- (2016) Xiaochun Liu et al. Oncotarget
- Targeting survivin as a potential new treatment for chondrosarcoma of bone
- (2016) Y de Jong et al. Oncogenesis
- Biomedical-grade, high mannuronic acid content (BioMVM) alginate enhances the proteoglycan production of primary human meniscal fibrochondrocytes in a 3-D microenvironment
- (2016) Ana Rey-Rico et al. Scientific Reports
- In vitro engineering of human 3D chondrosarcoma: a preclinical model relevant for investigations of radiation quality impact
- (2015) Dounia Houria Hamdi et al. BMC CANCER
- Alginate gel particles–A review of production techniques and physical properties
- (2015) Su Hung Ching et al. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
- Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
- (2015) Luyuan Li et al. PLoS One
- Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
- (2015) Johnny Suijker et al. Oncotarget
- Outcome of advanced, unresectable conventional central chondrosarcoma
- (2014) Annemiek M. van Maldegem et al. CANCER
- The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity
- (2014) Georg E Winter et al. Nature Chemical Biology
- An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing
- (2014) Jolieke G. van Oosterwijk et al. VIRCHOWS ARCHIV
- Advanced chondrosarcomas: role of chemotherapy and survival
- (2013) A. Italiano et al. ANNALS OF ONCOLOGY
- Doxorubicin, DNA torsion, and chromatin dynamics
- (2013) Fan Yang et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
- (2012) Jolieke G van Oosterwijk et al. BMC CANCER
- Clinical outcome of central conventional chondrosarcoma
- (2012) Andrea Angelini et al. JOURNAL OF SURGICAL ONCOLOGY
- Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model
- (2012) Jennifer Perez et al. PLoS One
- Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance
- (2011) J. G. van Oosterwijk et al. ANNALS OF ONCOLOGY
- Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens
- (2011) Hoa H. Truong et al. BIOMATERIALS
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
- (2011) Twinkal C Pansuriya et al. NATURE GENETICS
- Alginate: Properties and biomedical applications
- (2011) Kuen Yong Lee et al. PROGRESS IN POLYMER SCIENCE
- In Vitro and In Vivo Characterization of Nonbiomedical- and Biomedical-Grade Alginates for Articular Chondrocyte Transplantation
- (2011) Susanne Heiligenstein et al. TISSUE ENGINEERING PART C-METHODS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now